ArticleOncoimmunology2013
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Assessment of natural killer cell subpopulations in pediatric patients with transfusion-dependent β-thalassemia major.Clinical and experimental pediatrics · 2025Article
- A New Hope for CD56Frontiers in cellular and infection microbiology · 2020Article
- Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.BMC infectious diseases · 2019Article
- Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints.Cancer immunology, immunotherapy : CII · 2018Review
- Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Poorly cytotoxic terminally differentiated CD56Blood advances · 2018Article
- Expression of NKp46 Splice Variants in Nasal Lavage Following Respiratory Viral Infection: Domain 1-Negative Isoforms Predominate and Manifest Higher Activity.Frontiers in immunology · 2017Article
- Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression.Frontiers in immunology · 2017Review
- NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint.Oncotarget · 2016Article
- Natural killer cell mediated immunosurveillance of pediatric neuroblastoma.Oncoimmunology · 2015Article
- NKp30 isoforms in patients with chronic hepatitis C virus infection.Immunology · 2015Article
- First Trimester Pregnancy Loss and the Expression of Alternatively Spliced NKp30 Isoforms in Maternal Blood and Placental Tissue.Frontiers in immunology · 2015Article
- Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology · 2013Review
- Trial Watch: Proteasomal inhibitors for anticancer therapy.Molecular & cellular oncologyReview
- Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells play a prominent role at the intersection between innate and cognate immunity, thus influencing the development of multiple pathological conditions including HIV-1-induced AIDS. Not only NK cells directly kill HIV-1-infected cells, but also control the maturation and/or elimination of dendritic cells (DCs). These functions are regulated by the delicate balance between activating and inhibiting receptors expressed at the NK-cell surface. Among the former, NKp30 has raised significant interest since the alternative splicing of its intracellular domain leads to differential effector functions, dictating the prognosis of patients bearing gastrointestinal sarcoma, and B7-H6 has recently been identified as its main ligand. Since NKp30 is downregulated in CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.